What are the FDA-approved human ivermectin doses for different conditions?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
The FDA has approved human ivermectin in specific formulations and uses: oral tablets for certain parasitic worm infections and topical products for skin conditions such as head lice and rosacea; it has not authorized ivermectin to prevent or treat COVID‑19 [1] [2]. Oral tablets are manufactured in a 3 mg strength and are typically dosed on a weight basis—often as a single administration for the approved parasitic indications—while dosing beyond those indications is either off‑label or investigational [3] [4].
1. What the FDA has explicitly approved: parasitic infections and topical indications
The U.S. regulatory record is narrow: ivermectin tablets are FDA‑approved to treat intestinal strongyloidiasis and onchocerciasis (river blindness), and topical ivermectin products are approved for head lice and for rosacea‑type skin disease; those are the labeled, approved human indications under federal oversight [1] [2] [4].
2. How the approved oral drug is formulated and how dosing is handled
The oral tablet available for humans comes in a 3 mg tablet strength, and approved dosing for the parasitic indications is weight‑based and tailored to the condition, frequently delivered as a single dose though some infections require repeat dosing under clinical guidance; authoritative summaries and drug references describe the tablets as weight‑based and available in that 3 mg formulation [3] [2].
3. What the FDA and medical organizations say about non‑approved uses (notably COVID‑19)
The FDA has repeatedly stated it has not authorized or approved ivermectin for preventing or treating COVID‑19 in humans, and cautioned that available clinical trial data do not demonstrate efficacy for that purpose [1]. Major professional groups urged ending use of ivermectin for COVID‑19 outside clinical trials, and physician and pharmacist organizations warned against prescribing or dispensing it for COVID‑19 given the lack of supportive evidence [5].
4. Laboratory signals versus clinical reality: why dosing for COVID‑19 was not adopted
Laboratory work showed that ivermectin can inhibit SARS‑CoV‑2 replication in cell cultures, a finding that prompted further investigation but did not by itself translate to an approved human dose for COVID‑19 because the in vitro concentrations and safety margins differ from what is achievable or safe in people [6]. Large randomized clinical trials and platform studies testing higher or prolonged dosing regimens (for example, trials targeting 600 μg/kg daily in COVID‑19 research) have not demonstrated clinically meaningful benefit, and therefore no COVID‑19 dosing has been endorsed by regulators [7] [8].
5. Off‑label prescribing, veterinary products, and safety cautions
From a regulatory viewpoint, clinicians may prescribe an approved human drug off‑label for an unapproved indication in individual cases, but regulators and medical societies warn strongly against using veterinary ivermectin formulations in people because those products differ in formulation and concentration and carry poisoning risk [1] [4] [5]. Public health agencies tracked increased poison‑center calls and adverse events when people self‑medicated with animal products or inappropriate doses [4] [9].
6. Political and commercial pressures that muddy dosing discussions
Policy moves in some U.S. states to expand over‑the‑counter access or otherwise change distribution rules for ivermectin have created confusion: manufacturers and medical professionals emphasize that use should remain within FDA‑approved indications and dosing frameworks, while some state actions have argued for broader availability even as federal guidance cautions against non‑evidence‑based uses [10] [11] [9]. These conflicting incentives—patient demand, political decisions, industry statements, and regulatory caution—help explain why clear, universal public messaging about approved human doses and when to use them has been difficult to sustain [10] [11].
7. Bottom line for dosing: what can be stated with confidence
What can be stated unequivocally from the regulatory and clinical sources provided is that FDA‑approved human ivermectin exists as a 3 mg oral tablet and as topical preparations for dermatologic uses, that dosing for approved parasitic diseases is weight‑based (often a single dose for many indications), and that no FDA‑approved dose exists for COVID‑19—the latter remains unsupported by clinical trial evidence and discouraged by the FDA and medical societies [3] [2] [1] [5] [7].